• search

Novo Nordisk launches long acting basal insulin

Written by: Staff
|

Bangalore, May 13 (UNI) Novo Nordisk today launched Levemir, a novel predictable basal insulin analogue with a unique mechanism of prolonging action for people suffering from type 1 and type 2 diabetes in India.

Levemir provided predictable and cosnsitent control of blood glucose levels. This would enable blood glucose levels maintained within a very narrow range, especially during the night. It provided an opportunity for people with diabetes to achieve consistent dosing which facilitated optimal glycaemic control, the company said in a release here today.

Speaking about the launch, Melvin Oscar D'Souza, Managing Director of Novo Nordisk India said the company was the first in India to have short and long acting insulin analogue for adults and children.

UNI VK RKN1238

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more